Catalyst
Slingshot members are tracking this event:
Phase 1 SAD Data Evaluating SAGE-718 in Cerebrosterol Deficit Disorders, Anti-NMDA Receptor Encephalitis, and NMDA Hypofunction Due H2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SAGE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2017
Occurred Source:
http://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-third-quarter-2017-financial-results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Sad, Sage-718, Cerebrosterol Deficit Disorders, Anti-nmda Receptor Encephalitis, Nmda Hypofunction
